AZENT

OFFICIAL TITLE: SAFETY AND EFFICACY STUDY OF AZD9291 IN TREATMENT-NAÏVE PATIENTS WITH EGFR MUTANT NSCLC AND CONCOMITANT EGFR T790M PRETREATMENT.

PROJECT DETAILS

A PHASE IIA CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF OSIMERTINIB (AZD9291) IN FIRST-LINE PATIENTS WITH EGFR MUTATION-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AND CONCOMITANT EGFR T790M MUTATION AT TIME OF DIAGNOSIS.

THE PRIMARY GOAL IS TO EVALUATE THE EFFICACY OF OSIMERTINIB (AZD9291), IN TERMS OF THE OBJECTIVE RESPONSE RATE IN PATIENTS WITH ADVANCED NON-SQUAMOUS NSCLC WITH EGFR MUTATIONS AND THE EGFR T790M MUTATION AT DIAGNOSIS AS DEFINED BY RECIST 1.1 CRITERIA.

SAFETY AND EFFICACY WILL ALSO BE MEASURED.

 

AZENT AT CLINICALTRIALS.GOV

TUMOR TYPE

PHASE

NSCLC

II

21

7

Spain

N

SITES

COUNTRY

STATUS

Recruitment  closed

AZENT SITES

Hospital Universitari Sant Joan de Reus

SPAIN

Hospital Universitari Dexeus

SPAIN

Hospital Arnau de Vilanova de Valencia

SPAIN

Hospital Universitari Sant Joan de Reus

SPAIN

Complejo Hospitalario Universitario de Santiago (CHUS)

SPAIN

Hospital Universitario de La Princesa

SPAIN

Hospital Regional Universitario de Málaga (Hospital Carlos Haya)

SPAIN